{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:55:53Z","timestamp":1770911753637,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.berh.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T07:03:16Z","timestamp":1537426996000},"page":"415-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors"],"prefix":"10.1016","volume":"32","author":[{"given":"Jonathan","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.berh.2018.08.003_bib1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The assessment of spondylo arthritis international society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.08.003_bib2","article-title":"Methotrexate for ankylosing spondylitis","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/030097401753180318","article-title":"Clinical investigation of methotrexate in the treatment of ankylosing spondylitis","volume":"30","author":"Altan","year":"2001","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2018.08.003_bib4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/rheumatology\/41.11.1330","article-title":"Is methotrexate effective in ankylosing spondylitis?","volume":"41","author":"Roychowdhury","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.berh.2018.08.003_bib5","first-page":"1568","article-title":"Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial","volume":"31","author":"Gonzalez-Lopez","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.08.003_bib7","article-title":"Sulfasalazine for ankylosing spondylitis","volume":"11","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib8","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.08.003_bib9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2018.08.003_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/ard.2006.052878","article-title":"Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.08.003_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/1756-185X.13124","article-title":"A\u00a0randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis","volume":"21","author":"Khanna Sharma","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.08.003_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ard.2003.019174","article-title":"Six months open label trial of leflunomide in active ankylosing spondylitis","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.08.003_bib13","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/ard.2005.036491","article-title":"Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis","volume":"64","author":"van Denderen","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib14","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.08.003_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib16","first-page":"560","article-title":"Primary ankylosing spondylitis: patterns of disease in a Brazilian population of 147 patients","volume":"28","author":"Sampaio-Barros","year":"2001","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.08.003_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib18","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2018.08.003_bib19","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","article-title":"Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study","volume":"42","author":"Clegg","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2018.08.003_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s100670050027","article-title":"Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study","volume":"19","author":"Biasi","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/030097400750002021","article-title":"Methotrexate in the treatment of ankylosing spondylitis","volume":"29","author":"Sampaio-Barros","year":"2000","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2018.08.003_bib22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s10067-006-0460-6","article-title":"The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases","volume":"26","author":"Genc","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2018.08.003_bib23","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/ken207","article-title":"Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation","volume":"47","author":"Li","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.berh.2018.08.003_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","article-title":"Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment","volume":"58","author":"Breban","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.08.003_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2125.2011.04050.x","article-title":"Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis","volume":"73","author":"Ternant","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib26","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar3350","article-title":"Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study","volume":"13","author":"Mulleman","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.berh.2018.08.003_bib27","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.08.003_bib28","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3899\/jrheum.150389","article-title":"Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study","volume":"42","author":"Heinonen","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2018.08.003_bib29","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/art.39691","article-title":"The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial spondyloarthritis","volume":"68","author":"Nissen","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","article-title":"The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study","volume":"74","author":"Lie","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2018.08.003_bib31","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/art.39772","article-title":"Effect of comedication with conventional synthetic disease-modifying antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with spondyloarthritis: a prospective cohort study","volume":"68","author":"Sepriano","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2018.08.003_bib32","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.08.003_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2018.08.003_bib34","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/acr.20258","article-title":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register","volume":"62","author":"Kristensen","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.berh.2018.08.003_bib35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2018.08.003_bib36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib38","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2018.08.003_bib39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","article-title":"Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients","volume":"189","author":"Black","year":"1964","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.berh.2018.08.003_bib40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","article-title":"The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate","volume":"27","author":"Scarpa","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2018.08.003_bib41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2018.08.003_bib42","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A\u00a0randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"10012","key":"10.1016\/j.berh.2018.08.003_bib43","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.berh.2018.08.003_bib44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate efficacy in the tight control in psoriatic arthritis study","volume":"43","author":"Coates","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib45","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib46","first-page":"1302","article-title":"Measuring dactylitis in clinical trials: which is the best instrument to use?","volume":"34","author":"Healy","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2018.08.003_bib47","first-page":"241","article-title":"Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome","volume":"22","author":"Abu-Shakra","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib48","first-page":"469","article-title":"Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort","volume":"35","author":"Chandran","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.08.003_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.berh.2018.08.003_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib51","first-page":"894","article-title":"Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial","volume":"22","author":"Gupta","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2018.08.003_bib52","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2018.08.003_bib53","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/rheumatology\/35.7.664","article-title":"Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study","volume":"35","author":"Combe","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2018.08.003_bib54","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archderm.1990.01670280071013","article-title":"Sulfasalazine improves psoriasis. A double-blind analysis","volume":"126","author":"Gupta","year":"1990","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib55","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatology"},{"issue":"7","key":"10.1016\/j.berh.2018.08.003_bib57","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.08.003_bib59","first-page":"116","article-title":"Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study","volume":"186","author":"Mazzanti","year":"1994","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00296-001-0166-7","article-title":"Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis","volume":"21","author":"Sarzi-Puttini","year":"2002","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2004.024463","article-title":"A\u00a0randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis","volume":"64","author":"Fraser","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.08.003_bib62","first-page":"2274","article-title":"A\u00a0comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis","volume":"28","author":"Salvarani","year":"2001","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib63","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2018.08.003_bib64","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A\u00a0phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2018.08.003_bib65","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2018.08.003_bib66","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib67","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.08.003_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for \u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.berh.2018.08.003_bib69","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/jdv.14832","article-title":"Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis","volume":"32","author":"Papadavid","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.berh.2018.08.003_bib70","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"16","key":"10.1016\/j.berh.2018.08.003_bib71","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.berh.2018.08.003_bib72","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2018.08.003_bib73","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2018.08.003_bib74","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib75","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.berh.2018.08.003_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000606","article-title":"Design and rationale of the study of etanercept and methotrexate in combination or as monotherapy in subjects with psoriatic arthritis (SEAM-PsA)","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.berh.2018.08.003_bib77","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/ard.2009.119446","article-title":"Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis","volume":"69","author":"D'Angelo","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib78","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2018.08.003_bib79","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2018.08.003_bib80","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/ard.2007.085951","article-title":"Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis","volume":"67","author":"Spadaro","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.08.003_bib81","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:19:14Z","timestamp":1761499154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694218300408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1521694218300408"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2018.08.003","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}